(6S)-6-Phenyl-2,3,5,6-Tetrahydroimidazo[2,1-B][1,3]Thiazole

The chemical entity designated (6S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole constitutes the pharmacologically active S‑enantiomer of the imidazothiazole anthelmintic class, obtained as a crystalline free base with a specific optical rotation of +85° to +90° (c=2, water). The hydrochloride salt, formed by protonation at the imidazoline nitrogen, is the form incorporated into all major pharmacopoeial monographs owing to aqueous solubility exceeding 200 mg/mL at 25 °C and the absence of hygroscopic deliquescence that plagues the free base at relative humidity above 65%. This (6S) isomer demonstrates selective nematode nicotinic acetylcholine receptor agonism, depolarizing muscle membranes to produce spastic paralysis, whereas the (6R) enantiomer exhibits approximately one-fifteenth the affinity for the same target. The stereodescriptor is kinetically consequential: epimerization at C‑6 can occur via keto‑enol tautomerism when the material is exposed to alkaline pH above 9.0 or sustained thermal load beyond 60 °C, progressively eroding enantiomeric excess and simultaneously generating a compound with a divergent toxicological fingerprint.

The Clinical Imperative for Enantiopurity

A survey of regulatory filings between 1985 and 2000 confirms that racemic tetramisole—the DL‑mixture from which the (6S) form must be resolved—was progressively abandoned in human and companion‑animal medicine because the R‑antipode contributes disproportionate cholinergic side effects (salivation, tremor, bronchoconstriction) without meaningful anthelmintic gain. Contemporary pharmacopoeial standards therefore require a chiral purity floor of 99.0% enantiomeric excess for levamisole hydrochloride; documented deviations to 98.0% e.e. have triggered a narrowing of the therapeutic index in canine model studies, with emesis and transient ataxia appearing at doses as low as 8 mg/kg compared with the 10 mg/kg threshold at full enantiopurity. The US FDA’s 2000 withdrawal of racemic tetramisole from the over‑the‑counter veterinary market formalized a manufacturing expectation: multi‑ton batch records must demonstrate consistent chiral integrity not merely at release but after 36‑month stability storage at 25 °C/60% RH as defined by ICH Q1A(R2). Batch‑to‑batch variance in resolution efficiency is the dominant cost driver in (6S)‑6‑phenyl‑2,3,5,6‑tetrahydroimidazo[2,1‑b][1,3]thiazole production. The classical route employs L‑(+)-tartaric acid in aqueous ethanol, precipitating the diastereomeric tartrate salt with a theoretical maximum yield of 50% per crystallization cycle. Plant‑scale data from a GMP facility operating 2,000 L glass‑lined reactors indicate that maintaining the slurry at 5±2 °C during the 12‑hour ripening step limits the mother‑liquor loss of the desired diastereomer to 6–8%; an unplanned excursion to 13 °C during a single campaign resulted in a drop in precipitated diastereomeric excess from 99.5% to 94.1%, necessitating a complete reprocessing and solvent‑intensive re‑equilibration. The sensitivity to thermal fluctuations places a practical ceiling of 70–75 kg isolated free base per cubic meter of reactor volume without recourse to continuous‑flow crystallization technologies that are still at pilot scale. Monograph specifications for levamisole hydrochloride across the European Pharmacopoeia (Ph. Eur. 01/2008:0727) and the United States Pharmacopeia (USP 31‑NF 26) align in their requirement for identity, appearance, and purity, though harmonization is incomplete for the related‑substances thresholds. The table below delineates the key variance points that influence release decisions in a multi‑jurisdiction supply chain.

Quality Attribute	Ph. Eur. Limit	USP Limit	Typical In‑Process Release Value
Appearance of solution (10% w/v in water)	Clear, ≤ Reference Y6	Clear, colorless	Abs 0.02 at 420 nm
pH (10% aqueous)	3.0–4.5	3.2–4.2	3.7
Specific optical rotation (dry basis)	−120° to −127° (c=2, water)	−121° to −128°	−124°
Impurity A (tetramisole-related ketone)	≤ 0.3%	≤ 0.2%	0.05%
Any unspecified impurity	≤ 0.10%	≤ 0.10%	≤ 0.04%
Enantiomeric purity (chiral HPLC)	≥ 99.0% (S‑isomer)	≥ 98.5%	99.8%
Loss on drying (100–105 °C)	≤ 0.5%	≤ 0.5%	0.12%
Sulfated ash	≤ 0.1%	≤ 0.1%	0.03%
Heavy metals (as Pb)	≤ 20 ppm	≤ 20 ppm	≤2 ppm

The chiral HPLC method prescribed in both compendia employs a tris‑(3,5‑dimethylphenylcarbamate)‑coated silica column (250 × 4.6 mm, 5 µm) with a mobile phase of hexane:ethanol:diethylamine (90:10:0.1 v/v/v) at 1.0 mL/min and UV detection at 215 nm. Under these conditions, the (6S)‑enantiomer elutes at approximately 8.2 min, with resolution from the (6R)‑peak exceeding 2.5. A deviation in column temperature from 25 °C to 35 °C compresses the separation to 1.4, risking integration artifacts capable of masking a 0.8% R‑enantiomer excursion—an event documented during a laboratory qualification at a contract testing organization.

If Moisture Ingress Exceeds 60% RH During Micronization

Micronization of the hydrochloride salt to a D₉₀ below 20 µm—a prerequisite for uniform dispersion in feed premixes—introduces a process‑induced amorphous fraction detectable by modulated differential scanning calorimetry. When the relative humidity inside the jet‑mill chamber exceeds 60% at 25 °C, the amorphous domain adsorbs water sufficient to hydrolyze a trace fraction of the imidazothiazole ring, liberating 3‑(2‑aminoethyl)‑5‑phenylimidazolidine‑2‑thione, which tests positive for genotoxicity in an Ames fluctuation assay at concentrations above 50 µg/plate. Consequently, equipment qualification requires that nitrogen dew point in the micronization loop is held below −40 °C, and the milled powder must be filled directly into double‑polyethylene‑lined drums with desiccant packs achieving an internal headspace humidity of ≤15% RH within 4 hours. Stability batches stored under these conditions for 48 months show no degradation product above the reporting threshold of 0.05%. Veterinary dosage forms capitalize on the compound’s water solubility and rapid gastrointestinal absorption. An oral drench for ovine administration is typically a 7.5% w/v solution of levamisole hydrochloride equivalent to 60 mg/mL of the base, delivered at 7.5 mg/kg body weight. In cattle, the same dose achieves peak plasma concentrations of 0.8–1.2 µg/mL within 2 hours, with an elimination half‑life of 3.7±0.4 hours in plasma and a withdrawal period of 14 days for muscle and 60 hours for milk as established by the European Medicines Agency under MRL summary report EMEA/CVMP/055/95‑Final. Immunomodulatory applications in human oncology—formerly standardized as 50 mg oral tablets administered every 8 hours for 3 days every two weeks as adjuvant therapy for Dukes’ C colorectal carcinoma—have been summarized in the 1990 FDA approval of Ergamisol, though the product was discontinued in the United States in 2003; research‑grade material continues to be consumed in alkaline phosphatase inhibition assays at concentrations between 0.1 mM and 2 mM. The free base form, (6S)‑6‑phenyl‑2,3,5,6‑tetrahydroimidazo[2,1‑b][1,3]thiazole, melts at 60–61 °C and exhibits a log P of 1.8, sufficient to cause passive dermal penetration when handled as a fine dust. Industrial hygiene monitoring on a packaging line equipped with local exhaust ventilation at 0.5 m/s face velocity has recorded air concentrations below 0.1 µg/m³ when the free base is transferred under a nitrogen shroud, rising to 1.2–2.5 µg/m³ during manual scooping of open‑drum material at 40% RH, emphasizing the requirement for contained transfer systems even though the compound is not classified under EU directive 2017/2398 as a carcinogen, mutagen, or reproductive toxicant. The hydrochloride salt carries no such respirable exposure concern due to a vapor pressure below 0.01 Pa at 25 °C.

What Separates the 6S Conformer from Tetramisole in Bioassay Potency?

Tetramisole, the racemic (±)‑6‑phenyl‑2,3,5,6‑tetrahydroimidazo[2,1‑b][1,3]thiazole, melts sharply at 87–89 °C—roughly 27 °C higher than the 6S enantiomer—due to the formation of a racemic compound rather than a conglomerate in the solid state. This physical distinction has practical implications: while tetramisole can be stored at ambient warehouse conditions with no special inerting, the 6S‑enantiomer base must be kept at 2–8 °C under nitrogen to prevent both oxidative discoloration and localized melting during summer transit to Zone IVb climates. The differential pharmacology is summarized in receptor‑binding studies using [³H]‑cytisine displacement from L‑type nicotinic receptors of Ascaris suum muscle membranes: the (6S)‑isomer yields an IC₅₀ of 0.12 µM, whereas tetramisole requires 1.8 µM and the isolated (6R)‑isomer demands roughly 2.7 µM, confirming that the activity of the racemate derives almost entirely from its S‑half. A second table synthesizes the critical physicochemical distinctions that govern formulation route selection and regulatory filing decisions.

Property	(6S)-Levamisole Free Base	Levamisole Hydrochloride	Tetramisole (Racemic Base)
Molecular formula	C₁₁H₁₂N₂S	C₁₁H₁₂N₂S·HCl	C₁₁H₁₂N₂S
Molecular weight (g/mol)	204.29	240.75	204.29
Melting point (°C)	60–61	227–229 (dec.)	87–89
Aqueous solubility at 25 °C (mg/mL)	~8 (pH 9.5)	~210 (pH 3.8)	~12 (pH 9.5)
Specific rotation [α]²⁰D (c=2, water)	+85° to +90°	−121° to −128°	0°
Hygroscopicity	Significant above 65% RH	Non‑hygroscopic below 90% RH	Moderate, deliquesces above 80% RH
Chiral purity requirement	≥ 99.0% (S)	≥ 99.0% (S)	Racemic (±50% S)

The hydrochloride salt is, in practice, the only form supplied for GMP pharmaceutical manufacture. Its resistance to racemization in the dry state is superior to that of the free base: a forced‑degradation study storing both forms at 60 °C/75% RH for 30 days demonstrated that the hydrochloride retained 99.6% e.e. while the free base declined to 93.2% e.e., accompanied by the formation of the oxidation product 6‑phenyl‑2,3‑dihydroimidazo[2,1‑b]thiazole at 2.1%. Manufacturing sites that process the free base—typically as an intermediate during resolution or when preparing non‑aqueous formulations—employ vacuum drying at ≤35 °C and immediate back‑filling with argon to suppress the autocatalytic photo‑oxidation pathway that accelerates at wavelengths below 320 nm. In the global supply chain, the predominant differentiation between (6S)-6-Phenyl-2,3,5,6-Tetrahydroimidazo[2,1-B][1,3]Thiazole products lies not in the core molecule but in the particle engineering applied to the hydrochloride salt. Direct‑compression grades for tablet manufacture require a tapped density of 0.55–0.70 g/mL and a Carr index below 20, achieved through a slugging‑and‑sieving step that adds a 12% cost premium relative to the fine‑powder grade used in solution‑based drenches. Granulated premix grades, blended with lactose monohydrate to a levamisole base content of 8.0% w/w and subsequently diluted in feed to a final concentration of 80–800 ppm, must pass a 100‑mesh (150 µm) sieve with >95% recovery to prevent segregation during pneumatic conveying—a criterion that has been met consistently only when the API particle size distribution D₅₀ lies within 45–63 µm. Operations that source generic material with a broader D₉₀ of 120 µm routinely encounter 15–20% assay variability across 25‑kg feed bags, triggering out‑of‑specification investigations under 21 CFR 225.58. From a toxicological and ecological safety standpoint, the (6S) enantiomer’s acute aquatic toxicity has been classified as LC₅₀ (Danio rerio, 96 h) = >100 mg/L, placing it outside the trigger for hazard statement H400, whereas breakdown products formed under environmental photolysis at latitude 40° N in mid‑summer show a transient toxicity increase of 5‑fold before mineralisation. These data, generated according to OECD test guideline 203, inform the environmental risk assessment appended to European centralized marketing authorization dossiers. No specific occupational exposure limit has been promulgated by the ACGIH; in‑house industrial hygiene standards adopt an 8‑hour time‑weighted average of 0.5 mg/m³ (inhalable fraction) based on a read‑across safety factor of 10 from the no‑observed‑adverse‑effect level in a 90‑day rat inhalation study.